RVNC - Earnings call transcript Q1 2019 | Revance Therapeutics, Inc.

Due to licensing restrictions, you must log in to view earnings call transcripts.

Operator

Welcome to the Revance Therapeutics First Quarter 2019 Financial Results and Corporate Update Conference Call. [Operator Instructions].

As a reminder, this call is being recorded today, May 8, 2019. I would now like to turn the conference call over to Jeanie Herbert, Senior Director of Investor Relations and Corporate Communications for Revance. Please go ahead.

Jeanie Herbert

Gigi. you, Thank

of the the Chief on Toby from is released and Revance Chief Sjuts. Therapeutics, Joining today, ended Earlier Officer, call March Dan and Revance Head Joshi; Abhay Executive Officer, results Officer, Aesthetics Browne; President and Operating Dustin for us financial Dr. today Commercial, quarter Chief Schilke; XXXX. Financial XX,

releases, be release please added Relations Revance's received not www.revance.com. would you you've to Investor or receive to this list go news future the the section to website, like be If company's which distribution to found simply of can at

strategy this Revance's planned and precommercial make plans; XXXX company's will forward-looking are operations; the technologies. and call, and launch and to the potential and on results statements business current related uncertainties. guidance; involve XXXX forward-looking statements our expectations and During financial inherently of conference based risks clinical These anticipated statements, candidates management and product development including candidates; significant product

timing the changes the on to and expectations. on update XXXX. Our Revance future risks XX-K those from as will XX, to Dan include or ended Factors for in to reliance statements result as company these Dan? actual the of cautions be results February or undue over and and turn results could forward-looking a our result I to statements on new Risk December in a forward-looking factors SEC Browne. of events XX, in undertakes report with cause its information, statements forward-looking now as XXXX, not place no such anticipated events describes call any filed Form different of obligation differ you Factors duty statements section that from uncertainties. titled these materially could in the the annual year the

Daniel Browne

has DAXI, conference by DaxibotulinumtoxinA quarter Thank is our or you, unprecedented response for number one unmet neuromodulators next for targeted call. addressing standard physician then in cash-pay with you need year. to and afternoon, XXXX lines, glabellar and therapeutics first, $X.X and for segment market new Good first results. market. facial deliver injection, global patient in and Jeanie. reimbursed of and is proven a DAXI Revance duration in thank joining the creating aesthetics to long the in the rates we disrupt billion market neuromodulators, approval anticipate the introduction DAXI effect larger enduring and

in aesthetics first sheet. in quarter, and DAXI balance made glabellar progress our pipeline BLA strengthened the During advanced and on both we our the for therapeutics lines, further

neurosciences three a are: you business consumers DAXI update we experience our the each a providing In will two aesthetics, developed precommercial business. readiness which for me in activities and glabellar on are aesthetics, areas, I will launch just main begin be to of approval to upgrade by our and for natural, have the market-disrupting map look per underway. treatment treatments Let therapeutic and with long-lasting with road biosimilars. neuromodulator lines. first DAXI safe, Launch well year. aesthetics

April, In and successfully how the upgrade in to their country's approach. tank best practices. a position XX and this market innovation with are opportunity aesthetic of opinion engaged medical key designing hosted DAXI They we We on leaders within have smooth in our how into insights physicians. an to collaborated provided assessed think leading ensure

loud heard key clear messages. and also We X

and X just a First, treatments role opportunity in year play unlocks a a will major DAXI significant delivering consistent results with aesthetics.

increased not new unique list dose. strongly decreased results entrants. efficacy price an market DAXI's felt formulation profitability to duration concern third, market commoditization increased due exists to for and attendees attributable proprietary for were differentiated that and Second, And and DAXI's despite

seasoned leadership VP launch perfect support at studies in go-to-market strengthened addition commercial X thinking II years. is having Taryn our built we innovative team preliminary competitive the for marketing glabellar Conway of skills developing are as underway a busy also with launches of product drive, now that, crow's to specialty the brands in managed the feet. Marketing. support and recently lines the in are model. We Allergan veteran Her face addition Phase XX pharma, In we Taryn commercial lines, for upper to than have forehead and more and DAXI, infrastructure. our Also, in of growing

the provided preclinical further and time press update We expertise our on clinical an the submission. strengthen these our set. for will expect release, based from and line studies data data DAXI's results we that robust these progress on In BLA

which studies clinical X, indication, with will data an include X X package continue months. to for active compile BOTOX for largest up X,XXX the study followed for to and patients We BELMONT, aesthetic comparator XX the to SAKURA and DAXI

been parallel in develop have vial to vial. working also a We the in XX-unit to addition XXX-unit

BLA We tracking in are and drug includes This the potential the approval XXXX vials. BLA. are of product with and XXXX. to drug validation our submitting both fall We to completing launch on and substance stability our file now plan and in receive XX- XXX-unit

conditions. in value developing turn significant This and in widespread of Now fasciitis. dystonia, with to multiple a the Phase patients We cervical dystonia ongoing trial focused quality the drug's provide Phase of All which limb cervical spasticity enrolled clinical trials X application a through segment, Revance treatment and trial have chronic Phase a includes trial enrolling readouts neurosciences muscle in a X from to patients conditions, In business. III movement other of debilitating comprehensive year. the implications. in let me the change in scheduled are in trials potential II X all last long-lasting to and should spasticity, option could quality-of-life II patient this dramatically plantar a our the have half indications a life ability range line program upper muscle of billion-dollar DAXI broad therapeutics the movement, is later XXXX. top second therapeutic currently on pain in maximize shareholder for suffering and trials neurologic

to approved as our activities opportunity plantar quickly hired currently an cervical Dr. dystonia, oversee foot For cash-pay recently Revance, affliction. Dr. drug plantar treatment this we and held as clinical as often anxious science possible. spasticity, and BlackThorn medical to fasciitis painful to manage areas. see for are Mahableshwarkar neuroscience Mahableshwarkar reimbursed We drugs both support the limb led which therapeutic In approvals of roles patients fasciitis, normal development several upper there resume to and of the is for initiatives, help in key and Atul Prior programs Takeda, migraine. clinical director at to no

shareholder assets with have that for several update BOTOX. will of to benefits. value potential creating been a a developing would by on me our program. third Mylan provides key you A let value underutilized, Revance monetizing This on biosimilar otherwise program to biosimilar biosimilar program collaborate drive continues Finally, biosimilar enable It be shareholders. pillar also, DAXI. of the targeting approval, could lastly, subject neuromodulator to participate a therapeutic It in segment approved of aesthetic market long-acting And in the us to short-term with short-acting addition source portfolio nondilutive of would to the BOTOX allow program we are would segment targeting the funding. indications. and successful

will a viable. takeaways source a the long-acting us pathway from Our build minutes of biosimilar could DAXI. the indications potential XXX(k) growing is our a Biosimilar confirmed the to of our provide we principally In out premium ongoing that enable received royalty FDA, which revenue, April, biosimilar Advisory for from portfolio Initial face-to-face meaningful Meeting which meeting,

currently in development to under are discussions near-term a which Revance. could XXX(k) such plan pathway, to detailed on We Mylan milestone a payment lead with

the We will progression as share partnership more highlights. on our recent develops. the it details of That covers

begin first summarize call turn few to me the our Q&A to the let over quarter before Toby? Toby I'll we a have comments session. Now results, then financial closing

Tobin Schilke

you, strengthened XXXX from the Starting quarter the Fosun year-end quarter our our recognized equity from the equivalents balance offering. the sheet first $XXX,XXX and Thank XXXX Revenue cash, with we with balance, the collaboration. we with first million. payment for investments of $XXX Dan. quarter, In cash consisted Mylan upfront of our and short-term January ended

We expect advance the program partnership. additional we revenue to recognize Fosun development the and both biosimilar as

was stock-based go full, today excluding million. earnings won't so results And the and depreciation our issued financial in was compensation, $XX.X this $XX.X through call. it on The I outlines release OpEx details we million. Our

reiterating are XXXX We our guidance.

be expense, and $XXX of million expect range in million. in million and compensation, stock-based GAAP $XXX the to the expense $XXX range operating depreciation to million; operating We excludes to XXXX non-GAAP which of $XXX

We Revance's shares Dan. extend lines. for cash through XX.X as to outstanding million runway With the of approval back expect XXXX March to XXXX glabellar call our DAXI and were shares. fully XX, that, the million of anticipated with I'll turn diluted XX approximately

Daniel Browne

you, Toby. Thank

commercial We potential, in and disruptive DAXI's are both therapeutics. aesthetics confident in

expansion indications a on in and for progressing assure submission of BLA indications. compelling show our XXXX durability safety, a Moreover, and the and we a in We range DAXI anatomies laser-focused launch additional plans. are in pipeline and complete approval wide broad a of and of aesthetics finalizing are positioning ourselves assembling commercialization differentiated efficacy to to doses,

the potential now believe term. business opportunity open biosimilar Operator? the we and the our that, source the expansion the long by I'll us up for With in revenue an with Finally, both additional providing call of questions. to has near fuel

Operator

our Seamus Fernandez And question Guggenheim. Instructions]. from first [Operator is from

Seamus Fernandez

of guys of we've So and us there? that and Can think And a I we milestone, you cervical profile things milestone impact we're you indication. potential separately, you that we of likelihood sense also then importance -- say how the in about anticipate dystonia investors to longer-acting just can the guys a the give the heard that that just and a as this a just approval would first the biosimilar magnitude relative us you impactful one XXXX general the timing, be off, to in sense the you the would physicians to general think of when about of talking are of in, of the terms see milestone? coming is give guess,

Daniel Browne

neurology play areas to about But on that and change several board pain able think neurology, thinks and to in indications, without past role. a the cervical not therapeutic the It's profile. it's going of be not the AAN in that, one changing I across profoundly of meeting very of interesting, had only only dystonia, response group as both how is number coming neurologists safety the this DAXI spoke you to would came it's away to, a broadly indications, weekend, rates therapeutic being the in we meetings, the another key Seamus, that durability, that out but say I DAXI movement. know, excited we more the advisory

therapeutics, represents biosimilar on that good Mylan approach, that. about with have a and of think, think potential the might to So not a be we additional a milestone would challenge, do but the to go. think time that to the we recognize that accordingly. We're working we balance the XXX(k). the color between I review. We very the sort really way been first And the would value that the I But something feel relative this of give And is it's will, have for biosimilar, and viable can the that you milestones something a on aesthetics we'll meaningful authorities development long think given have regulatory reinforce think and will if under it. we articulated, we progress I plan, still this so hopefully, meet feasibility

Tobin Schilke

flow as on million, contingent I positive effect any have paid Upon million is payment is milestones. milestone of that development can the regulatory cash clinical $XX net upfront collaboration, progress flow The and provide further of on cash Mylan the signing a in to this a the Revance that of bit and more nonrefundable neutral. color we $XXX well.

So when take the through. you that modeling consider milestone,

Operator

Our Annabel next from from is Stifel. Samimy question

Annabel Samimy

to the Can it expect is ahead that What for behind any you of biosimilar. this emerge we see line the if we and in impact? a year? its to indications? plan terms this thinking development emerges time of sort you it therapeutic the something expect are going biosimilar of -- can to, And Just therapeutic broader is as back biosimilars of this indications,

Daniel Browne

do any the indications development be improved will dystonia refine wait have we expect not one not think development to other for this indications and development DAXI again, But so -- that, at DAXI, agreed cervical of of in we just front be Annabel, I year. more or front would of to plan this the -- have to we'll plan the once the to would in need and in It point. approval probably see.

Annabel Samimy

of the follow-up a just the guess, have more And taking the to, market. gained we've I investments guess toxin, Okay. I opportunity some essentially market? like to the create I I segment the are top to Can the a efforts that could with long-acting space it bifurcate us of last an now granularity get a of if the you parallel market. you yet making the week, little in seems some around of and bit your over that penetrate grow and with players think efforts question. share you're right that

there? you that can anything So share with us

Daniel Browne

I as the to rates. durability physicians. and understand I think with you to well both of physicians speak just response they patients the And as the met importance both surgery, and get, plastic dermatology, think neurologists have that both aesthetic we've

that it's peer most journals innovated it's review of end is just frankly, But and new. this is about think that will from very and North first, in some investigators data use new in of story. the the supported quite most I by so clinically up This meaningful in And think not America. we prominent how Because innovative, some the prominent I people often. tell

growth expanding advance extended data not need that a providing set, for not its response others the growing all the time, first to decades. different think I unsatisfied have duration it's they rates, in able has And technologies current entrant. clinical data have will rate to soon been just improved improve not And put Revance when unmet go and So can response about a to for and rates. It's another and its be have tried a where has about market it's together haven't set successful. at We it, others been first preclinical label tried. an been through this because about duration and the filing that and

not guess, to and can the the with year. natural sidelines are who it patient are only on that with physicians that waiting resonate based and look see resonates that, in an imagine with of imagine to X I patients competing jump chasing products upper large downward got who story the on whether they that's look for aesthetic have that's not the first story price the in We understand don't that essentially, treatments number are going you Can spasticity, the can that dystonia back cervical think at And but a times? other go a price, twice are by a for that. to convenience patients treatment That limb resonates around a today I you and who's a time quite they think, they patient? a year going a to on that the first neuromodulators resonate aesthetic is are Street, would frankly, I or go twice in. concept that to with to Wall whether time,

that, get And and strong about so we're with year. approved can think I next we expect that excited a we label

Operator

is Cacciatore from & Cowen Company. next Ken Our question from

Kenneth Cacciatore

XX you in moving your I for to -- you can but thought filing, just said manufacturing, also ask had then leaders. disclosure wanted Just on -- about that's to you if preparations said the -- vial, understand then forward? work think BLA XXX-unit And so for talk doing and just about you you're all CMC the correctly

But I Can just in I they terms a mark. of thinking giving lot early about a year, folks advice some making you not to of pricing, meeting to get like about think also every about the were from that's this patient premium pricing. of And you X-month I'm is the talked maybe likely going in but a understand had you the room. the that exact sounds you? talk maybe number.

how we to and shorter-acting handle So we again? it's them that. rescue if doesn't wanted how get you'd handle that? Would know the a we to just patient So toxins them? there, a premium-priced product do just lose do How

Daniel Browne

start missed follow-up. Yes. three ask manufacturing. for I'll I the the color Ken, with the thanks on a please If any, questions.

the our one setback simply sector just because going X in around in comprehensive been the very resulted to on stability, the even in because process for stronger been to most submission that's companies be despite it's in you've is package work not the validation a ever not time. do. an XX-unit space long been neuromodulation view, I of is top delay, And XXX-unit I we it, this areas. to of all the filing. my I mean, time updated be that right the have ideal, in the trying and following the Look, in approval. neuromodulators. a thing this BLA it's Ken, in view, side our but data streams today, with we compiling additional most the the around issue the even of transparent wanted in the is release it's to think, result the the believe that assembled time but press had additional this recent CMC We've And provide think addition of line will

So X near on a another products it's coming done supplement. to term and years and approval both I or the now, invest X.X better on think to have having after this focus back get versus postapproval

do. others what endpoint, leaders X the product, seen formulation or unique doing. results what key cannot very No neuromodulator advice proprietary been provide This opinion other before. is, with Focus dose think the don't decades. of in So -- Relative take-home the one look, this this key that. is doing world what that I peptide. around on treatment twice think we tried in are. sort concept a the is with to There of I good no leaders, is about who messages around feel around this, unique. treatment consumers, resonate think X year also touch to is we are on the to anywhere has those focus botulinum And -- this formulation going for that giving other who of from not uses can have I no and And regardless those they DAXI is opinion DAXI

both the and it to consumers tell easy do be will you us. of an stay the on because what tell Tell So that to and it it to focused story can physicians story treatment. in their in or in for to get have once patients twice. hands who year. They can a They around X come or They it. come for times come X don't

it's all X to They Now today with months. every But median products. point, true don't not a to duration, patient, last to months. be that's is existing your the X going X

and Some the of last population. XX of different days. other sort segments Males

it to it and naive. all We it users You're below gender. previous across in neuromodulators to of duration in saw see We segments. in those going saw XX. We extended see above

broad price, to response way this best So to section. we're the is relative this think, seeing to that across grow outcomes. durability is perspective, for fundamentally outcome. rates The about provide And of propagation and space better our a I

premium a are We product.

with We are we've where an and to durability not to as make therapeutic it reflective the also that population, us or handicap make of into side, if we our innovative product. that got think it's compelling I sure And pricing even advantages that possible response sure DAXI. the broadest on incorporate you doesn't more, want much, but rates see

We'll settles So not the y got buy introductory on a experience. of and come I going think in get strategy a free. with strategy pursue. but to better based the price, and that to we're the x out we've I see to XX be That's have sort that's on you believe months. market where we're don't going It'll that outcomes

Operator

question Piper from Our Jaffray. David from next is Amsellem

David Amsellem

So Dan. just a hypothetical,

that? to pricing, plan this you product, you know we dynamics, face are are respond you're entering you've realities regarding the so about how over premium certain address in pricing next the in a that some DAXI? to talked premium the Let's being XX experience, if see I you say pricing to and that do speak? in we the but do And you lot B, real guess, do market I degradation changes with a that do what's, will, staring as some how see XX if market real months, there

Daniel Browne

And I from work in They today. I you strategy. our products. price go the it's competition David, fair think commoditization a the good about all think is all perspective on is where same. companies, a question. is They're good That market based

And not. be think still us, that where get market others, where this that as can is of aesthetic There strategically, We're of And the only that the not you articulate the decades constraining this think, it's experience. that's grow going to a outcome. seeing most Today, been as a we see so itself fabulous And and experience market for price. is price right? do meaningfulness XX% the of today, way argue market. about may on market the least we ultimately I at research, all a bear may And It's sort will your today, to better that are compete we have go discount traction to that opportunity to price. segment of going is to I But in change. that to done there's we leaders about our look, job. don't that or And out. where

has leader Revance neuromodulators. went think utmost eyes We I the safety predictability what in of wide respect built this for and the of sort they in into the our market of the open. with landscape this

to our whole We grow. what our biosimilar. another have market and are we But expect we not level, in If If what's whole sites it type who the will experience. SAKURA us, investigators, that and in believe performance matches the I it that of a experience going sort leaders that, as key commercial what have and those opinion about and is and the to XX a thesis label that's been will away, take that that the short-acting around of deliver that follow were product, we program. and it's

focus. hypothetical the I not believe necessarily and doesn't the we're to going, of want more haven't based I kind We but it's up end And type with focus of that's space. don't longer we type innovation, had this but performance to going role approach where someone this side. that's that we'd the to biosimilar how a want If where on and on we then of rates, not that experience. we where be was think duration response that's for Now mean

David Amsellem

helpful. And then more one That's question. Okay.

And be tox most be market to want to multitude on also who named, to just that be are not So couple. think named they're not of said the down your of is practices who a that I CEO, based shall an has on road, reality? is line assertion contemplate In especially trained and crowded, biosimilars going stick as I more years get and wanted leader And market that the mean, to in not as you going we thinking. the products. words, thoughts other several becomes shall that that to

Daniel Browne

I again I'll myself, for just of speak and their sort thesis. others let support

and are multiple be great? to I have thesis. think even to long-acting right? you're a that on look, puck support think a the of him the but stock going Because years multiple -- where products, recognize of the great to David, going have What going going to going, work literature going to short-acting, to Gretzky talk argue player. puck long-acting. is they're based centers going. I'm That's I'm right? to going But is -- are market to the on dose, made that there They're they're made that programs. trying they're Wayne is the what starting XX not others to to to going it, not or hockey is, have doesn't going I products. same is movement about they this the go future why where increase long-acting. That's where They're a

pick that go aesthetics, long-acting. work going doesn't experience. think fillers, don't of Because want going a body be physician practices, pick be will better they're whether differently. going practices. be happened They're I examples any of that point, they'd short-acting they is the whether those there products neuromodulators, I to have whether what those, and multi-brand think the but not other patients to will they'd be the they're they'd one multi-brand the of to some in And There contouring to same be group be with it, elsewhere. So when

going on you're think up that's but practices, long-acting pick and you don't the have the they're to to break short-acting. why And it but multi-brand, I you're some how single-brand going expands. in out Dustin, that? market to have going So

Dustin Sjuts

Yes.

and this margin, the new sense value if the that if drives to only in, entrants that to duration, to reach shown honestly, to value else there innovation I summit get this trained can clear quickly. the want the the is they had. that market consumer it's a train. product. as come products. offer has. something we it and have relates on think something of at had the the look product in desire the nothing Today, the to on train That That's can that physician being one I we've that you some then increased will want product, desire at no and different, isn't high that and new it efficacy what Quite bring else train They

Daniel Browne

was many think very as aesthetics And what as strong synergistic leader disease, I chronic into the be In they And should David, and it's on successful. it aesthetics as that approach. just you be brand balanced negative, it's need made the that construe it's know that say who because a balanced When to and effective. think combined, some carryover therapeutic just experience this they safe debilitating ways, powerful. patients one the other our point people will focused aesthetics thesis. see had that is, I across got we're platform they pricing, to see that and been because patients space, I'll having that approach more consideration on therapeutics there both on sort to think imitating to be We powerful effective. on And initial strategy is rates more some if indications. a in I grow is want need applications. you it's very reject response but of Yes,

Operator

Tsao Our next question H.C. is Douglas Wainwright. from from

Douglas Tsao

the Dan, for XXX-unit filing maybe vials. just, just of So I the sort terms of issue the in understand delaying

importance filing to to Just great up curious of what did at such a point delay little it bubble sort bit? the potentially

Daniel Browne

the wanted we Look, question. of in this. front right Doug, thanks jump out to for

that very was until up to recently, going into thought as is meet It ambitious. this And had that target. really it. recognize we complex think a good I We we know. a biologic, shot you

You've have or a companies at neuromodulator one all I time. space the for I these. mentioned And before, this another to at as covered point long think wrestle

time it the to do commercialization get to XXX-unit be additional thought of all, good the stability The I into the with validation frankly, I and quite Revance clinical taking, all stages in XX. It think, the just had to to But back front do process me strategy, of additional that right to straightforward. longer be came was this addition we transparent workloads is with feel our us have neuromodulator a think for helpful right like that investment vial trials reminds that. take And early to in is and David the the of year. in XXX we it. with around a an than thing out are going really and the about it think of the to I the conversation both we're Piatt relatively potent I was, going it the very

need be manufacturing. I one companies that think thing all the your on the on to focused is

this. state-of-the-art well. with back group a infrastructure, service have experienced think I facility and of who come people a will very intellectual with that are And We an working horsepower very it's an

aspects this few right the in months long-term to with the multiple work do. to thing through a was So units

Operator

from is Timothy from William Instructions]. [Operator And our Lugo Blair. next question

Myles Minter

Myles on for Tim.

I'm process, a the and manufacturing challenges shelf those life. just there manufacturing XXX-unit to in any that that the two on wondering between the is of following whether Just vial. unique XX- whether in and stability difference translates so potential the

Daniel Browne

differences and pick do package. to having XXX-unit. It's the your in No. no you include both generating It's differences just the There life. no XX- Abhay, are in up There data. set please? that just on that, between is shelf to data formulation want about

Abhay Joshi

No.

no. of think I terms unique any challenges, the is in answer

process it's a completing think right. the I that is sure done work matter make validation to of

Myles Minter

migraine the design from of And how Obviously, meetings update think your marketplace that? with also Great. had everyone on But saying on dystonia about also program? What neurologists if Fantastic. trial potentially you any on about you leader do talking sharing extra erosion the AAN. on the that thinking CGRP, migraine very else. much neuromodulatory that cervical the the not market there's just at in updates as excited I prevention? And is you've And about? thoughts biologics? been the Any you're the

Daniel Browne

peptide, and unique And at of understands easily. me more got the community very -- the anatomies, more it will, they've at this dosed. is across based because formulation. jumped longer experience, really if conversation I neurology really more on not This had. it's a that it tissues. soft think things two we There's this One Yes. combination a They indications, got neuromodulator you this it's very, is

so other the commercially the available think this and I over unique And borne was products out. concept that itself really different really

neuromodulators, is there indications you I the is a pain be more I'll think I durable. be other responsive, one role think the for neuromodulator, on to going continue is headache, for to there longer to better need going mentioned that a a continue and to a what a say

for Now under Revance being which that up is a ends priority determination. form does

couple of talked for smart how neuromodulators. community about CGRPs believe place be think, the us to and it. market evolves of that people unanimously, to in through I be we with Anything trying But thinkers market it it's imagine We have this the -- about trying We're lot to the were tighten you as see is the And going the of We're with look work on of respond a study away, responders going I is who good trying patient. that population take going be to are a the I and best work lot better could like, a are that and to DAXI. And to else? neuromod and headache that? finding know want Abhay, calls, not opportunities. we're there These up are that and think you suggestions. what study we've design. would helping some through can if that

Abhay Joshi

No.

also marketplace, we this key was despite feel mold and CGRPs I from continue given that initiate year of further and year. will out the experts next in CGRPs to new leaders TOXINS a definitely fact designs later that which can AAN with at come would for thing think that I coexist. the came and we one definitely that our the with into And design work most different looking sometime likely this early or opinion trial

Operator

is next Difei Our from question from Yang Mizuho.

Alexander Lim

respect have in for add up your to your portfolio with view, the bundle? and discussions Alex on market, KOLs. a topic important it, if came wondering is your I'm the how filler With your This is own to Difei. aesthetics in to eventually

Dustin Sjuts

Listen, this is Dustin.

differentiated important DAXI it's I us when allows can a DAXI. and is profile works, an unlock on thing product for the to has it's obviously and The fact think no bundling that there new that potential differentiation. experience, focus

types Of DAXI. at on different all course, focus look we business DAXI, opportunities that is will our of innovations development and help but mainly support

don't the So a filler believe we space. in to necessary compete is

there. value at do that we opportunities out However, are look different

Operator

you. back the I'm I to like call for this further to Thank no closing turn time, showing questions. would Dan Browne remarks. over At

Daniel Browne

you, Operator. Thank

in our let Palos And Conference in you'd in Ranchos or when June, be know in the at if at call. to us area RBC schedule May, of In we'll Healthcare we're Conference a New Sachs Please Jeanie the meet Verdes. York. like Healthcare terms Goldman be travel your we'll in schedule

each and I'd good have with your that, you like today, of a you. Thank So for to day. thank time

Operator

in concludes gentlemen, and the This today's Ladies you thank participation for your conference. program.

You may now disconnect.

Revance Therapeutics (RVNC) 9 May 192019 Q1 Earnings call transcript